Background-Re-endothelialization is delayed after drug-eluting stent (DES) implantation. In this setting, neointima is more prone to become lipid laden and develop neoatherosclerosis (NA), potentially increasing plaque vulnerability. Methods and Results-Optical coherence tomography and near-infrared spectroscopy with intravascular ultrasound were used to characterize NA in 65 (51 DES and 14 bare-metal stents) consecutive symptomatic patients with in-stent restenosis. Median duration poststent implantation was 33 months. Optical coherence tomography-verified NA was observed in 40 stents with in-stent restenosis (62%), was more prevalent in DES than bare-metal stents (68% versus 36%; P=0.02), and demonstrated significantly higher prevalence of thin-cap neoatheroma (47% versus 7%; P=0.01) in DES. Near-infrared spectroscopy assessment demonstrated that the total lipid core burden index (34 [interquartile range, 12-92] versus 9 [interquartile range, 0-32]; P<0.001) and the density of lipid core burden index (lipid core burden index/4 mm, 144 [interquartile range, 60-285] versus 26 [interquartile range, 0-86]; P<0.001) were higher in DES compared with baremetal stents. Topographically, NA was classified as I (thin-cap NA), II (thick-cap NA), and III (peri-strut NA). Type I thin-cap neoatheroma was more common in DES (20% versus 3%; P=0.01) and in areas of the stented segment without significant in-stent restenosis (71%). Periprocedural myocardial infarction occurred only in DES (11 versus 0; P=0.05), of which 6 (55%) could be attributed to segments with >70% in-stent restenosis. By logistic regression, prior DES was the only independent predictor of both NA (odds ratio, 7.0; 95% confidence interval, 1.7-27; P=0.006) and periprocedural myocardial infarction (odds ratio, 1.8; 95% confidence interval, 1.1-2.4; P=0.05). Conclusions-In-stent thin-cap neoatheroma is more prevalent, is distributed more diffusely across the stented segment, and is associated with increased periprocedural myocardial infarction in DES compared with bare-metal stents. These findings support NA as a mechanism for late DES failure. (Circ Cardiovasc Interv. 2013;6:507-517.)
I n vascular homeostasis, a functioning endothelial layer inhibits the development of de novo atherosclerosis. After balloon angioplasty and stenting, there is extensive mechanical denudation of the endothelium and subsequently endothelial regeneration. Impaired healing of the endothelium, such that occurs with drug-eluting stents (DES), 1 facilitates lipid deposition within neointima and leads to the development of neoatherosclerosis (NA). 2 Pathological and imaging reports have demonstrated that NA is more common and occurs earlier in DES compared with bare-metal stents (BMS). 2, 3 Clinical imaging studies of DES-related in-stent restenosis (ISR) by optical coherence tomography (OCT) have identified that >75% of patients presenting with unstable angina have thin-cap or disrupted neointima with overlying thrombi. 4 However, although systematic in vivo imaging data are not available for BMS, it is reported that more than one third of these patients present with acute coronary syndromes 5 and have evidence of atherosclerotic plaque within aspirates of definite stent thrombosis. 6 Taken together, there remains a need to characterize NA in BMS compared with DES in vivo. We characterized neointimal composition of ISR in both BMS and DES by means of a multimodality imaging approach using OCT and near-infrared spectroscopy (NIRS) combined with grayscale intravascular ultrasound (IVUS). 7, 8 Methods From August 2011 to July 2012, OCT, NIRS, and IVUS were performed on 65 consecutive patients who had previously undergone stent implantation (14 BMS and 51 DES) and subsequently presented with recurrence of symptoms and angiographic ISR (>50% diameter). After imaging, 63 patients were deemed to have significant ISR and underwent repeat percutaneous coronary intervention (PCI) according to the appropriate use criteria. 9 PCI procedures were performed according to current standard guidelines with technique and the use of pharmacological agents at the discretion of the operator. Periprocedural myocardial infarction (MI) was defined as a postprocedural biomarker elevation >3× the upper limit of normal for creatine kinase-MB or cardiac troponin I measured 4 to 24 hours after PCI according to the Third Universal Definition of Myocardial Infarction Consensus Document. 10 For inclusion, all patients met the following criteria: PCI was performed; OCT, NIRS, and IVUS measurements were obtained in the culprit vessel before any intervention; ≥1 appropriately timed (between 4 and 24 hours after PCI) postprocedural cardiac biomarker measurement (creatine kinase-MB or cardiac troponin I) was available to determine the occurrence of periprocedural MI; there was no angiographic evidence of intracoronary thrombus; and an acute MI was not in progress at the time of imaging. Exclusion criteria were hemodynamic instability and an inability of the imaging catheter to cross the ISR lesion or left main or saphenous vein graft lesions. The clinical, procedural, and imaging data were obtained from an institution review board-approved interventional database of the Mount Sinai catheterization laboratories. Image analysis was performed at Mount Sinai Medical Center.
OCT Imaging and Analysis
OCT image acquisition was performed with a commercially available C-7 system using a 0.019-inch ImageWire (LightLab Imaging, Westford, MA) after NIRS and IVUS imaging. The artery was cleared of blood by applying continuous flush delivery of iopamidol (Isovue; Bracco Diagnostics, Princeton, NJ) at a flow rate of 3.0 to 4.0 mL/s. Stent and reference segments were assessed by computerized planimetry (Image J; National Institutes of Health, Bethesda, MD) using OCT and IVUS. Neointima was defined as the tissue between the luminal border and the outer border of the stent struts or the internal elastic lamina if it could be visualized. Neointimal area was calculated as stent area minus lumen area, and % neointimal was calculated as neointimal area divided by stent area. Stent underexpansion was defined as minimal stent area <5 mm. 2, 11 Significant neointimal area was defined as % neointimal area >70%. Culprit lesions were defined as areas of the stent with ISR >70% and nonculprit as the remainder of the stented segment. NA was defined as a signal-poor region with diffuse borders. 12 Thin-cap neoatheroma (TCNA) was defined as fibrous cap thickness at the thinnest part with mean of ≤65 μm from 3 adjacent measurements within the stented vessel. 13 Multiple OCTdefined TCNA-containing neointima were separated by ≥3 mm. OCT neointimal rupture was a break in the fibrous cap that connected the lumen with the underlying lipid pool. 14 Thrombi were masses protruding into the vessel lumen, discontinuous from the surface of the vessel wall and with a diameter ≥250 μm. Red thrombi were characterized by signal-free shadowing with high-backscattering, and white thrombi by signal-richness with low-backscattering. 14 The entire stented segment (5 mm proximal and distal to the stent) was analyzed per mm (5 frames). Stent strut coverage was assessed as previously described. 15 All reported OCT parameters required the agreement of 3 observers (Z.A., T.R., B.M.) who were blinded to the clinical and procedural characteristics. To test for interobserver variability of the qualitative OCT analysis for NA, all cross sections within the restenotic lesions where NA was identified were selected and analyzed independently by another observer not involved in the primary data analysis. One of the observers repeated the analysis after 1 week to assess the intraobserver variability.
NIRS and IVUS Imaging and Analyses
NIRS image acquisition was performed simultaneously with IVUS imaging (TVC; InfraRedx, Burlington, MA) as described previously. 16 The chemogram, a culmination of ≈80 chemical measurements per millimeter of artery placed into a predictive algorithm, calculated the probability of lipid being present for each 2-mm section of artery. The lipid core burden index (LCBI) was used as a quantitative summary metric of the presence of lipid in the entire scanned region. The chemogram was analyzed off-line with Lipiscan LS107.001rB software to allow calculation of the LCBI per total area scanned, per stented segment (+4 mm from the stent edges), per stent, per 2 mm, and per 4 mm. Quantitative volumetric IVUS analysis was performed as described for OCT. 17
Coregistration of Intravascular Images
A method was established to ensure accurate coregistration among OCT, IVUS, NIRS, and the coronary angiogram. The radio-opacity of the imaging element and radio-opaque marker on the NIRS catheter permitted the interventionalist to identify the location of the catheter and imaging element in relation to target vessel landmarks detected by coronary angiography. All procedures used a standardized protocol. (1) The imaging catheter was advanced ≈17 mm distal to the distal edge of the stent. This was chosen based on the optical light being 7 mm proximal to the distal marker on the OCT catheter. (2) Based on this, NIRS and IVUS were started ≈10 mm distal to the distal edge of the stent. A flag was placed on the chemogram corresponding to the distal reference vessel (10 mm distal to the distal edge of the stent), at the distal edge of the stent (as identified by IVUS), at the mid-segment of the stent, at the proximal edge of the stent, and at the proximal reference vessel (10 mm proximal to the proximal edge of the stent). Cine angiography was recorded at each of these landmarks
WhAT IS KNOWN
• Optical coherence tomography is considered as the gold standard for diagnosis of neoatherosclerosis.
• Neoatherosclerosis is more common and occurs earlier in drug-eluting stents compared with bare-metal stents.
WhAT ThE STUDY ADDS
• Near-infrared spectroscopy is able to detect smaller pools of lipid within the stented vessel wall than optical coherence tomography; however, as only patients with optical coherence tomography-visualized neoatherosclerosis had periprocedural myocardial infarction, the clinical use of this increased sensitivity may be limited.
• In drug-eluting stents, neoatherosclerosis occurs earlier, is more common, and develops more diffusely along the stented vessel with thinner cap and greater total lipid core than bare-metal stents.
• Periprocedural myocardial infarction as a result of drug-eluting stent in-stent restenosis treatment is attributable not only to lipid core from culprit in-stent restenosis but also to lumen-centric neoatherosclerosis remote from the culprit site but within the treated segment.
to ensure appropriate coregistration. Coregistration with OCT was performed post hoc using the length marker on the OCT longitudinal image, ensuring accurate assessment of the stented vessel.
Statistical Methods
The Kolmogorov-Smirnov test was used to determine whether data were normally distributed. Interobserver and intraobserver variability is expressed as κ coefficient of agreement. Descriptive statistics are presented as means±SD or medians with interquartile ranges and compared with the t test or Mann-Whitney U test, respectively. Categorical data are expressed as frequency and percentage and compared with χ 2 or Fisher exact test where appropriate. When comparing multiple groups, data were analyzed by ANOVA with Bonferroni post-test for multiple testing for parametric data. Estimations are presented with 95% confidence intervals (CIs). Conventional levels of significance (0.05) were applied throughout. Forward stepwise logistic regression was performed to identify predictors for NA using a statistical cutoff of P=0.20 on multivariable analysis with bootstrap refinement. Statistical analysis was undertaken using SPSS for windows version 20 (Chicago, IL) and S Plus version 6 (Seattle, WA).
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the article as written.
Results

Baseline Clinical and Procedural Characteristics
The clinical and procedural characteristics comparing patients with BMS and DES are presented in Table 1 and by DES type in Table I in the online-only Data Supplement. The median time poststent implantation was 33 months (interquartile range [IQR], 16-61). The indication for initial stent implantation was similar in both groups. History of hypertension, previous myocardial infarction, and use of aspirin and statin therapy were more common in the DES group. There were no episodes of acute stent thrombosis. Quantitative angiographic and invasive imaging data are presented in Table 2 and Table II in the online-only Data Supplement by DES type. By angiography, a focal pattern of ISR (14% versus 49%; P=0.03) was more common in the DES group, and a diffuse pattern of ISR (79% versus 43%; P=0.03) was more common in the BMS group. There was a trend toward greater percent diameter stenosis in the DES group (62% versus 53%; P=0.08).
OCT-Based Characterization of NA
NA was defined as a signal-poor region with diffuse borders on OCT and was distinguished from pre-existing fibroatheroma. NA was topographically classified into 3 distinct patterns (types I-III), and pre-existing fibroatheroma was referred to as type IV (Figure 1 ). Type I or TCNA lesions displayed ≥1 area of thin cap (<65 µm), with the signal-poor region and diffuse borders indicative of lipid accumulation located between the lumen and the stent struts. Type II or thick-cap NA lesions displayed signal-poor region with diffuse borders between the lumen and the stent struts, but no area of cap was <65 µm thick. In type III or peri-strut NA, the signal-poor region with diffuse borders was located between or around the stent struts. In type IV pre-existing fibroatheroma, the signal-poor region with diffuse borders was separated from the stent struts by a fibrous band and was located between the stent struts and the adventitia, representing pre-existent atherosclerosis from the original lumen-obstructing lesion. Interobserver or intraobserver variability for the qualitative OCT assessment was as follows: 0.91/0.89 for presence of NA, 0.86/0.83 for TCNA, 0.82/0.84 for thick-cap NA, 0.76/0.79 for peri-strut NA, and 0.77/0.82 for pre-existing fibroatheroma.
OCT-verified NA was present in 40 (62%) stented vessels and 20% of all cross sections (376/1881). In-stent neointimal rupture was present in 6 (15%) patients and occurred exclusively in patients with NA (Table 3 ). There was no difference in the incidence of NA in patients with or without previous MI ( 
NIRS Imaging Characteristics of NA
Using NIRS, lipid was detected within stented vessels in 58 (89%) patients. Median total stent LCBI was 25 (IQR, 10-74), LCBI/mm 0.81 (IQR, 0.28-2.81), maximum LCBI/2 mm 159 (IQR, 71-351), and LCBI/4 mm 90 (IQR, . There was an inverse correlation between LCBI and cap thickness (0.22; 95% CI, 0.05-0.39; P=0.01) over the length of the stent. Based on a positive predictive value of 97%, a minimum LCBI/4 mm of 68 was the threshold for OCT-verified lipid core within the neointima ( Figure I in the online-only Data Supplement). In 18 (28%) stented vessels, NIRS-identified lipid was not detected by OCT. Lipid deposition in these cases was minimal without a discernible lipid core or TCNA.
As it was unclear what influence the metallic stent struts had on the chemographic assessment of lipid core plaque, we performed postmortem imaging of a stented coronary artery with NIRS and OCT followed by histology ( Figure 2 ). Coregistration with ex vivo angiography and OCT identified that NIRS was able to detect lipid, despite the presence of stent struts.
Comparison of ISR Characteristics in BMS and DES
The incidence of NA by duration of implant was significantly shorter in DES compared with BMS, with relative time difference in keeping with stent generation ( Table 4 and Table III in the online-only Data Supplement). The shortest duration to development of NA was 111 days (type I) in the DES group and 295 days (type III) in the BMS group. NA was significantly more common in DES versus BMS (68% versus 36%; P=0.02), with significantly more TCNA (24 versus 1; P=0.01) Table 3 ).
We next compared ISR characteristics in culprit (>70% ISR) versus nonculprit areas of the stented segment ( , with the signalpoor region with diffuse borders located between the lumen and the stent struts. Type II, thick-cap lesions display no area of thin cap (>65 µm), with the signalpoor region with diffuse borders located between the lumen and the stent struts. Type III, peri-strut NA (PSNA) where the signal-poor region with diffuse borders is located around the stent struts. Type IV, pre-existing fibroatherma (PEFA), where the signal-poor region with diffuse borders is between the stent struts and the adventitia, representing native pre-existent atherosclerosis. Top, Representative OCT images (white arrow, lipid; gray arrow, stent struts; asterisk, TCNA). Bottom, Lipid chemograms (black arrow, lipid core burden; blue line, maximal lipid detection).
had NA and were in DES. When morphological patterns of NA were assessed, we found type I NA to be more common in DES (20% versus 3%), with the majority 17 (71%) occurring at nonculprit sites within the stented vessel ( Figure 3A ). Type III NA was more common in BMS (36% versus 20%; Figure 3A ).
There was no difference between DES stent types and stent generation in the incidence of NA (Table IV in the onlineonly Data Supplement). However, lipid location was significantly different among the different DES groups (P=0.009; Figure 3B ), with a higher proportion of type III in paclitaxeleluting stents. Comparisons of BMS with the different DES are available in the online-only Data Supplement (Tables I-IV in the online-only Data Supplement).
Multivariable analyses revealed that the increased risk of NA in DES (odds ratio, 7.0; 95% CI, 1.7-27; P=0.006) was independent of other covariables (Table 6 ). Baseline serum creatinine and high-density lipoprotein showed a trend toward being independent predictors of NA (Table 6 ).
Periprocedural MI
Periprocedural MI was only detected in the DES group (22% versus 0%; median troponin I, 4.0 [IQR, 1-5]; P=0.05). Patients with periprocedural MI were significantly more likely to have luminal (type I/II) versus abluminal NA (type III/IV; 63% versus 37%; P=0.02) across the stented segment ( Figure 4 ). Of the 11 patients with periprocedural MI, 6 (55%) had NA (LCBI 4/mm, 130 [IQR, 90-243]) at the culprit site with 2 (18%) TCNA ( Table 5 ). All 5 of the remaining patients with periprocedural MI had luminal (type I/II) NA (LCBI 4/ mm, 96 [IQR, 46-211]) within the treated segment at a site remote from the culprit ISR ( Table 5 ). Use of cutting balloon, predilation, stent implantation, and postdilation were similar between the DES and BMS groups as was degree of balloon oversizing and maximal inflation pressures negating the potentially confounding effect of different intervention strategies on periprocedural MI (Table V in the online-only Data Supplement). There was a trend toward increased incidence of periprocedural MI with the use of cutting balloons for lesion preparation (29% versus 15%; P=0.08). Logistic regression analysis of predictors of periprocedural MI revealed only stent type as a predictor on univariable analysis (odds ratio, 1.8; 95% CI, 1.1-2.4; P<0.05).
Discussion
In this study, we characterized NA in vivo in consecutive symptomatic patients with ISR. Using multimodality optical imaging, we report several key observations. The prevalence of lipid within neointimal hyperplasia after stent implantation is high and is present diffusely across the stented vessel. We observed lipid deposition within stented segments of coronary artery, assessed by NIRS, in 89% of these patients, whereas in 62% lipid could be visualized within the neointima by OCT. Using careful coregistration, we determined that an LCBI >68 on NIRS was most predictive of OCT-visualized lipid within the neointima. NA was associated with significantly reduced minimal cap thickness, with plaque rupture occurring exclusively in these patients. We observed striking differences in the incidence and features of NA comparing BMS and DES, including greater prevalence and earlier occurrence of NA, thinner cap, and more TCNA with greater total lipid burden and density in DES. Furthermore, NA was more common and had greater LCBI and lipid arc in the culprit area of ISR in DES, but TCNA at this site was infrequent. Finally, periprocedural MI occurred exclusively in DES, with approximately half of the events attributable to NA within the culprit ISR and half to luminal type I/II NA remote from the culprit site but within the treated segment.
Recent reports have suggested NA as a possible pathway for late stent failure, in particular for DES. 4, 18, 19 Results of 5-year follow-up from SIRIUS, 20 RAVEL, 21 and TAXUS VI 22 trials, along with registry data from j-Cypher, 23 showed a late catch-up phenomenon angiographically, which has since been confirmed by IVUS. 24, 25 Our findings suggest a potential mechanism for these findings. When we analyzed plaque characteristics per millimeter of stented vessel at sites of culprit (defined as areas of ISR >70% within the stented segment) versus nonculprit areas, we uncovered several important findings. NA was more common at the sites of culprit lesions in DES but not BMS, and this was associated with significantly greater LCBI and lipid arc. However, rather than finding TCNA in these culprit lesions, we unexpectedly found higher cap thickness, despite higher lipid content compared with nonculprit areas of the stent. In fact, we found that the majority of TCNA and in-stent intimal ruptures did not occur within the area of tightest stenosis. Taken together, these findings allow for speculation of a unifying hypothesis for the late catchup phenomenon. NA in DES develops diffusely in a lumencentric manner caused by impaired endothelial regeneration as a result of drug elution across the entire stented surface. Subsequently, in TCNA, which also develops diffusely across the stented vessel, intimal rupture and its subsequent healing do not compromise luminal area because the stent maintains its scaffold function. Finally, however, the completed healing and vascular remodeling may ultimately manifest as fibrotic late ISR with high lipid burden and thick cap. Approximately 1.5 million patients undergo PCI in the United States each year. 26 Given real-world DES ISR rates of 10% 27 and a resurgence in the use of BMS, the annual incidence of ISR is estimated to be well above 100 000 cases. Treatment of these patients remains a significant clinical problem. Pathologically, DES ISR with NA represents a form of accelerated atherosclerosis seen commonly in saphenous vein grafts, where lesions are characterized by a structurally distinct and particularly aggressive form of atherosclerosis, with eccentric friable plaque deemed secondary to severe endothelial denudation or dysfunction. 28 In our study, we found a trend toward increased incidence of periprocedural MI with the use of cutting balloons for lesion preparation. In concert with the diffuse nature of lumen-centric NA in DES, it is possible that the cutting balloon penetrates lipid core plaque in areas of TCNA and type II NA in ISR region as well as in areas remote from the culprit site but within the treated segment. This may lead to lipid embolization and potentially myonecrosis. This In the stented segment, OCT images showed evidence of plaque rupture again, with signal-poor regions with diffuse borders suggestive of extensive lipid necrotic core (c) and a more distal stented segment (d) without lipid. E, Corresponding histology images of the proximal vessel showed early necrotic core with superficial macrophages and speckled calcification (a) and small residual thrombus (b). The proximal stented segment showed underlying plaque rupture with extensive necrotic core (c), whereas the distal stented segment showed no lipid accumulation (d), again corresponding with the chemogram in (C). *indicates stent strut. presumption is supported by the finding that of the 11 periprocedural MI, 6 had NA at the culprit site with 2 TCNA and the remaining 5 had nonculprit area luminal (type I/II) NA within the area treated by the cutting balloon.
OCT has been used in previous studies to classify composition in ISR in both BMS [29] [30] [31] and DES. 19 However, these classification systems have focused more on the appearance of the plaque over time in different generations of stents as opposed to the topographical distribution comparing stent types directly. This distribution, evaluated per millimeter of the entire stented segment, differed markedly between DES and BMS and also between generations of DES. In BMS, the proportion of type III peri-strut NA was higher, in keeping with the predominant site of inflammation after stent implantation. 2, 32, 33 However, in DES, there was a predominance of type I TCNA, in keeping with delayed re-endothelialization, endothelial dysfunction, and the accumulation of subintimal lipid deposition. 2 Thus, the localization of NA is the major benefit of OCT imaging in patients with ISR. The clinical relevance of NA localization is the potential avoidance of areas within the stented segment that have high lipid burden or luminal (type I/II) NA. Indeed, the incidence of periprocedural MI was considerably higher in luminal (type I/II) NA in DES in our study, and these events may be associated not only with immediate adverse outcomes, such as no-flow or slow reflow, but also with adverse long-term effects. [34] [35] [36] [37] [38] [39] Importantly, the higher rates of periprocedural MI in luminal (type I/II) NA also suggest that the accepted definition of thin-cap fibroatheroma in de novo atherosclerosis 40 may not hold the same clinical use for NA.
In addition to OCT that has been used in previous studies, our study also used NIRS to characterize lipid within stented vessels. The use of NIRS permitted the identification and quantification of lipid whose presence could not be determined by other intravascular imaging modalities and in this sense provides an incremental advantage compared with description of the plaque composition alone described previously. 19, [29] [30] [31] Using careful coregistration we determined that an LCBI/4 mm of >68 best determined OCT-visualized NA with a positive predictive value of 97%. We detected lipid in 28% of stented vessels by NIRS that could not be reliably detected by OCT. However, because periprocedural MI did not occur in vessels where lipid was detected by NIRS but not OCT and lipid was detected in almost all stented vessels (89%), the clinical use of NIRS/IVUS compared with OCT is limited. Nevertheless, NIRS allowed us to validate the presence of lipid using a second methodology that may overcome some of the shortcomings of OCT, such as the inability to discern NA from the metal strut penetration into pre-existing plaque, accumulation of fibrin, or luminal macrophages, all of which are identified on OCT as a typical appearance of a thin bright line with trailing shadows. 2
Limitations
The present study has several important limitations. First, each of the stented vessels included in this analysis was an independent sample that is unable to provide a true natural history of NA in the absence of a longitudinal study design. Second, although unselected, the patients we studied were relatively stable from a clinical perspective. Third, unlike previous reports on this topic, we were unable to find a time-dependent relationship on the development of NA. We included unselected consecutive symptomatic patients, and by virtue of this, our time since stent implantation ranged ≈10 years. In keeping with the natural history of stent evolution, the older stents tended to be bare-metal and newer stents, second-generation DES. Fourth, we do not have coregistered imaging and histological validation of our topographical NA classification. The addition of NIRS imaging to OCT does, however, validate the presence of lipid within stented vessels, and histological evidence of such localization has been described. 2 Fifth, it must be mentioned that all of the stent platforms included in this analysis are coated with durable polymers. The biological response and thus tissue characteristics to bioerodible polymers are currently unknown. Future studies investigating NA on the various polymer platforms will allow us to determine the relative contribution of drug and polymer to the NA response. Finally, our sample size was relatively small, and as such intergroup comparisons between generations of DES are prone to type II statistical error.
Conclusions
In-stent NA is common and diffuse. It occurs earlier in DES, with more TCNA, and is associated with more periprocedural MI compared with BMS. These findings support NA to be a mechanism for late DES failure.
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